Eleuthero / Siberian Ginseng

Metadata

Approved Indications

Commission E (Germany)

• Positive monograph (1991)
• Approved indication: “As a tonic in times of fatigue and debility, declining capacity for work and concentration, and during convalescence”
• Notable: This is one of the earliest formal Western regulatory endorsements of an adaptogenic herb

ESCOP

• ESCOP monograph published (2009 edition)
• Indication: “Decreased mental and physical capacities such as tiredness, weakness, exhaustion, and loss of concentration; during convalescence”
• Note: ESCOP monograph represents peer-reviewed scientific compilation

EMA/HMPC

• Community herbal monograph adopted (8 May 2008): EMEA/HMPC/680615/2007
• Category: Traditional use registration
• Approved indication: “Traditional herbal medicinal product used as an adaptogen in case of symptoms of asthenia such as fatigue and weakness”
• Age: Adults and adolescents over 12 years
• Duration: Up to 2 months; consult a doctor if symptoms persist beyond 2 weeks

Pharmacopoeial Recognition

• European Pharmacopoeia 10th edition (2020): Quality monograph for Eleutherococcus root
• British Pharmacopoeia (2014)
• Japanese Pharmacopoeia XVII (2016)
• American Herbal Pharmacopoeia (Upton et al., 2016)
• State Pharmacopoeia of the Republic of Belarus (2007)

Agreement/Disagreement

• Remarkably strong consensus: Commission E, ESCOP, and HMPC all agree on essentially the same indication (fatigue, weakness, debility). This is one of the strongest regulatory concordances of any herb in this module.
• However: All three bodies rely heavily on traditional use data and the Soviet-era research legacy rather than modern high-quality RCTs. The HMPC explicitly notes that “there is insufficient evidence from clinical trials” and classification is based on traditional use plausibility.

Conditions Treated

• Fatigue and weakness (asthenia) — primary approved indication
• Declining mental and physical performance
• Convalescence after illness
• Stress adaptation (adaptogenic)
• [Traditional/Russian]: Prevention of respiratory infections, enhancement of physical endurance, immune support in elderly
• [Component of Kan Jang]: Upper respiratory tract infections (in combination with Andrographis)
• [Preliminary evidence]: Cognitive support, athletic performance enhancement

Mechanism of Action

Active Compounds (Eleutherosides)

Adaptogenic Mechanisms

1. HPA axis modulation: Regulation of stress hormone (cortisol, ACTH) release under chronic stress conditions. Normalization rather than simple stimulation or suppression. [Source: PMC12605232]

2. Anti-inflammatory and immunomodulatory: Inhibition of NF-kB activation, MAPKs, and Akt pathways. This dual anti-inflammatory/immunomodulatory effect is proposed as the basis for the adaptogenic action. [Source: Frontiers Pharmacology, 2025]

3. Neuroprotective: Increase in brain-derived neurotrophic factor (BDNF). Cognitive benefits may derive from this pathway.

4. Heat shock protein induction: Eleuthero may increase HSP70 and HSP72 expression, protecting cells under stress conditions. This mechanism is shared with Rhodiola and represents a molecular signature of adaptogenic activity.

5. Beta-endorphin pathway: Eleutheroside B (syringin) specifically enhances beta-endorphin secretion from the adrenal medulla and stimulates peripheral opioid receptors, contributing to analgesic and mood-modulating effects.

6. Immune enhancement: Polysaccharides enhance macrophage phagocytosis and NK cell activity. Clinical studies in elderly populations showed some evidence of improved immune parameters [UNCERTAIN — quality limited].

Clinical Evidence Summary

Systematic Reviews

Brekhman’s Soviet-era research (1960s-1980s)

• Thousands of subjects studied in Soviet military, athletic, and occupational health contexts
• Reported benefits: improved physical endurance, resistance to cold and altitude, reduced sick days, enhanced cognitive function
• Critical limitation: Most studies do not meet modern methodological standards (inadequate blinding, unclear randomization, not published in peer-reviewed English-language journals)
• [Source: Pubmed 34087398 — narrative review of Russian literature]

Vogler et al. (1999) — Systematic review

• Concluded that the quality of clinical evidence was insufficient to recommend eleuthero for any indication

Modern assessment

• “High heterogeneity and low quality of clinical trials in connection with the lack of proper standardization of E. senticosus preparations make it impossible to assess the effectiveness” [Source: PMC12605232]

Key Individual Trials

Kan Jang Evidence (Combination with Andrographis)

• Multiple RCTs (see Andrographis for details)
• The contribution of E. senticosus to Kan Jang’s clinical effects is difficult to isolate from the Andrographis component
• Panossian et al. proposed synergistic mechanisms but direct comparative studies (Kan Jang vs. Andrographis alone) are limited

Evidence Quality Assessment

• Central problem: The most impressive evidence comes from Soviet-era research that does not meet modern standards. Modern Western-quality RCTs are few and often negative or inconclusive.
• The herb’s regulatory acceptance (Commission E, ESCOP, HMPC) is based more on historical/traditional use plausibility than on robust modern clinical data
• This creates an uncomfortable gap between regulatory status and current evidence quality

European vs. US/Anglophone Consensus

Safety Profile

Contraindications

• Hypertension: Commission E lists arterial hypertension as a contraindication. [CONTESTED — modern evidence suggests effect on blood pressure is minimal and bidirectional]
• Children under 12: HMPC restriction
• No contraindication for autoimmune disease was listed (unlike Echinacea)

Drug Interactions

• CYP2C9 inhibition: Eleutherosides inhibit CYP2C9, affecting metabolism of warfarin, NSAIDs (ibuprofen), tolbutamide, glyburide, losartan, phenytoin, and many other drugs. [Source: DrugBank, SelfDecode]
• CYP2E1 inhibition: Also documented; affects metabolism of acetaminophen, ethanol, some anesthetics
• Digoxin: Case report of falsely elevated digoxin levels (interference with digoxin immunoassay rather than true pharmacological interaction). [Source: MSKCC]
• Antihypertensives: Possible additive or antagonistic effects (data conflicting)
• Anticoagulants: CYP2C9-mediated increase in warfarin levels theoretically possible
• Insulin/hypoglycemics: Some evidence eleuthero may affect blood sugar; additive risk
• Overall: Drug interaction risk is MODERATE (CYP inhibition)

Side Effects

• Very well tolerated at recommended doses
• No signs of toxicity in clinical trials with healthy volunteers, children, or elderly [Source: PMC12605232]
• Animal toxicology: No toxic effects in guinea pigs at single oral dose of 6.0 g/kg or 14-day repeated dosing at 3.0 g/kg/day
• Rare reports: Insomnia (if taken late in day), mild GI discomfort, headache
• Historical concern about “ginseng abuse syndrome” (nervousness, insomnia, elevated BP) was largely associated with misidentified products or excessive doses

Pregnancy/Lactation

• Pregnancy: Limited human data. One animal study found no teratogenic effects with eleutherosides at 10 mg/kg/day for 16 days in rats. Not recommended during pregnancy by most authorities due to insufficient safety data.
• Lactation: Insufficient data. Not recommended.

Clinical Dosage

Commission E Recommended Dose

• Dried root: 2-3 g daily
• Extract (fluid extract 1:1): 2-3 mL daily
• Duration: Up to 3 months, with 1-month break between courses

HMPC Recommended Dose

• Dry extract (DER 15-25:1, ethanol 28-40%): 192-240 mg daily in 2-3 divided doses
• Dry extract (DER 17-30:1, ethanol 30-40%): 225-270 mg daily in 2-3 divided doses
• Duration: Up to 2 months; doctor consultation if symptoms persist beyond 2 weeks

Tincture/Liquid Extract

• Tincture: 20-40 drops, 3 times daily for 30 days (Russian tradition)
• Standardized extract: 100-200 mg twice daily (standardized to >1% eleutherosides)

Key Commercial Products

• Eleutherococcus extract (various European manufacturers): Registered THR products in EU
• Kan Jang (Swedish Herbal Institute/Bittner): Combination with Andrographis (see Andrographis)
• Endurox (Pacific Health Laboratories): Athletic performance product (US market)
• Various tinctures and dried root products (herbal pharmacies)

Sources

• EMA/HMPC: Community herbal monograph on Eleutherococcus senticosus (Rupr. et Maxim.) Maxim., radix (EMEA/HMPC/680615/2007, adopted 2008)
• EMA/HMPC: Assessment report on Eleutherococcus senticosus (Final)
• EMA/HMPC: Summary for the public — Eleutherococcus root
• Commission E Monograph: Eleutherococcus senticosus (1991)
• ESCOP Monograph: Eleutherococci radix (2009)
• Panossian A, Wikman G. “Evidence-based efficacy of adaptogens in fatigue, and molecular mechanisms related to their stress-protective activity.” Curr Clin Pharmacol. 2009;4(3):198-219.
• Bleakney TL. “Deconstructing an adaptogen: Eleutherococcus senticosus.” Holist Nurs Pract. 2008;22(4):220-224.
• Davydov M, Krikorian AD. “Eleutherococcus senticosus (Rupr. & Maxim.) Maxim. (Araliaceae) as an adaptogen: a closer look.” J Ethnopharmacol. 2000;72(3):345-393.
• Schaffler K et al. “No benefit adding eleutherococcus senticosus to stress management training in stress-related fatigue/weakness.” Pharmacognosy Research. 2013;5(3):209-214. (Pubmed 23740477)
• Kuo J et al. “The effect of eight weeks of supplementation with Eleutherococcus senticosus on endurance capacity and metabolism in human.” Chin J Physiol. 2010;53(2):105-111.
• Szolomicki S et al. “The influence of active components of Eleutherococcus senticosus on cellular defence and physical fitness in man.” Phytother Res. 2000;14(1):30-35.
• Todorova V et al. “Eleutherococcus root: a comprehensive review.” Front Pharmacol. 2025;16:1683795. (PMC12605232)

Connections

• Rhodiola: Fellow adaptogen with HMPC monograph; Rhodiola has stronger modern clinical evidence
• Andrographis: Combined with Eleuthero in Kan Jang product; shared Panossian research lineage
• Astragalus: Both are adaptogens with immune-enhancing properties; Astragalus lacks any EU regulatory recognition
• Echinacea: Eleuthero is sometimes described as “adaptogenic immune support” vs. Echinacea’s “acute immune stimulation”